An Open-Label Trial With TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Etravirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Janssen R&D Ireland
- 01 Apr 2009 Actual patient number (212) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Actual patient number (212) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.